Ubiquitin Drug Discovery and Diagnostics Conference - targeting E3 ligases.
The Ubiquitin Drug Discovery and Diagnostics Conference, held in Philadelphia, included topics covering the role of E3 ligases in disease. This conference report highlights selected presentations on E3-E2 ligase interactions, the SCF cyclin F ubiquitin ligase complex, and targeting HectH9 and KF-1 E3 ligases. Pharmaceutical research discussed includes E3 programs from Progenra and efforts to modulate the Parkin ligase at Elan Pharmaceuticals.
Johnston
Jennifer A
JA
Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, CA 94080-7021, USA. jennifer.johnston@elan.com
D000818:Animals; D055808:Drug Discovery; D006801:Humans; D008025:Ligases / Q000378:metabolism; D051379:Mice; D058990:Molecular Targeted Therapy; D044843:SKP Cullin F-Box Protein Ligases / Q000037:antagonists & inhibitors / Q000378:metabolism; D013379:Substrate Specificity; D025521:Tumor Suppressor Proteins; D025801:Ubiquitin; D043743:Ubiquitin-Protein Ligase Complexes; D044767:Ubiquitin-Protein Ligases / Q000037:antagonists & inhibitors / Q000378:metabolism
D025521:Tumor Suppressor Proteins; D025801:Ubiquitin; D043743:Ubiquitin-Protein Ligase Complexes; C502830:HUWE1 protein, human; D044843:SKP Cullin F-Box Protein Ligases; D044767:Ubiquitin-Protein Ligases; C111567:parkin protein; D008025:Ligases